转移性激素敏感性前列腺癌强化治疗期间睾酮突破与结局:ARASENS与LATITUDE试验
该研究对ARASENS和LATITUDE两项III期试验的实验组进行事后分析,评估治疗期间血清睾酮突破>35 ng/dL与临床结局的关联。LATITUDE中突破与更差的总生存相关(校正HR 1.49,95%CI 1.07-2.08;P=0.019),而ARASENS中总生存和CRPC的总体关联无统计学显著性。这些队列内发现属探索性,不能确立因果关系或临床睾酮目标。
要点
- LATITUDE试验中睾酮突破>35 ng/dL与更差总生存相关(校正HR 1.49)。
- ARASENS试验中睾酮突破与总生存和CRPC的总体关联无统计学显著性。
- 发现属探索性,不能确立因果关系、治疗机制差异或临床睾酮目标。
核心结论
- 在LATITUDE试验中,治疗期间睾酮突破>35 ng/dL与标志点后更差的总生存相关。
- 在ARASENS试验中,睾酮突破与总生存和CRPC的总体关联无统计学显著性。
- 这些队列内发现属探索性,不能确立因果关系、治疗机制差异或临床睾酮目标。
研究设计与样本
- 对ARASENS(达罗他胺+ADT+多西他赛;NCT02799602)和LATITUDE(醋酸阿比特龙+泼尼松+ADT;NCT01715285)III期试验实验组的事后分析。
- 采用队列特异性固定窗口标志点分析,暴露定义为治疗开始后至LATITUDE第147天或ARASENS第266天期间任何 eligible 睾酮结果>35 ng/dL。
- 排除治疗开始/第1天和治疗结束时测量;随访从标志点开始;主要终点为总生存。
主要发现
- 标志点时LATITUDE有564例、ARASENS有578例患者可分类用于总生存分析。
- LATITUDE中突破与更差总生存相关(校正HR 1.49,95%CI 1.07-2.08;P=0.019);PFS方向相似但不精确(HR 1.40,95%CI 0.98-2.00;P=0.065)。
- ARASENS中总生存(HR 1.18,95%CI 0.85-1.62;P=0.322)和CRPC(HR 0.86,95%CI 0.60-1.23;P=0.397)的总体关联无统计学显著性。
- 探索性分段模型提示CRPC存在时间变异(交互作用P=0.028)。
关键数值与推荐
- 睾酮突破阈值:>35 ng/dL。
- LATITUDE标志点窗口:治疗开始后至第147天;ARASENS:至第266天。
- LATITUDE总生存校正HR 1.49(95%CI 1.07-2.08;P=0.019);ARASENS总生存HR 1.18(95%CI 0.85-1.62;P=0.322)。
临床怎么用
- 解读结果时需注意:LATITUDE中睾酮突破与更差总生存相关,但ARASENS中未观察到统计学显著关联。
- 这些探索性发现不能用于确立临床睾酮目标或改变治疗决策。
- 治疗期间睾酮监测的意义需在进一步研究中验证。
局限性
- 为事后分析,属探索性,不能确立因果关系。
- 不能确立治疗机制差异或临床睾酮目标。
- ARASENS中总体关联无统计学显著性,且CRPC存在时间变异提示需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether treatment-period serum testosterone breakthrough >35 ng/dL is associated with clinical outcomes during intensified therapy for metastatic hormone-sensitive prostate cancer. PATIENTS AND METHODS: We performed post hoc analyses of the experimental arms of the ARASENS (darolutamide plus androgen deprivation therapy [ADT] and docetaxel; ClinicalTrials.gov identifier NCT02799602) and LATITUDE (abiraterone acetate plus prednisone and ADT; NCT01715285) phase III trials. Cohort-specific fixed-window landmark analyses classified exposure as any eligible testosterone result >35 ng/dL after treatment initiation and through Day 147 in the LATITUDE trial or Day 266 in the ARASENS trial. Treatment-initiation/Day-1 and end-of-treatment measurements were excluded. Follow-up began at the landmark. The primary outcome was overall survival (OS); the LATITUDE progression-free survival (PFS) and the ARASENS time to castration-resistant prostate cancer (CRPC) were progression endpoints. Multivariable Cox regression was primary; landmark and time-dependent sensitivity analyses were also performed. RESULTS: At the landmark, 564 LATITUDE and 578 ARASENS patients were classifiable for OS. In the LATITUDE trial, breakthrough was associated with worse OS (adjusted hazard ratio [HR], 1.49, 95% confidence interval [CI] 1.07-2.08; P = 0.019); the PFS estimate was directionally similar but imprecise (HR 1.40, 95% CI 0.98-2.00; P = 0.065). In the ARASENS trial, the overall associations were not statistically significant for OS (HR 1.18, 95% CI 0.85-1.62; P = 0.322) or CRPC (HR 0.86, 95% CI, 0.60-1.23; P = 0.397). Exploratory piecewise modelling suggested time variation for CRPC (interaction P = 0.028). CONCLUSION: Testosterone breakthrough >35 ng/dL was associated with worse post-landmark OS in the LATITUDE trial, whereas the overall associations with OS and CRPC in the ARASENS trial were not statistically significant. These within-cohort findings are exploratory and do not establish causality, a difference between treatment mechanisms, or a clinical testosterone target.
引用
- Xiao X, Ni X, Zhao Y, et al. Testosterone breakthrough and outcomes during intensified therapy in metastatic hormone-sensitive prostate cancer: the ARASENS and LATITUDE trials. BJU Int. 2026. PMID: 42833883. doi:10.1111/bju.70474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。